Grifols SA engages in the production of plasma derivatives. The company is headquartered in Sant Cugat Del Valles, Barcelona and currently employs 23,833 full-time employees. The company went IPO on 2006-05-17. The firm organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.
Follow-Up Questions
Who is the CEO of Grifols SA?
Mr. Jose Ignacio Abia is the Chief Executive Officer of Grifols SA, joining the firm since 2024.
What is the price performance of GIFLF stock?
The current price of GIFLF is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Grifols SA?
Grifols SA belongs to Biotechnology industry and the sector is Health Care
What is Grifols SA market cap?
Grifols SA's current market cap is $0
Is Grifols SA a buy, sell, or hold?
According to wall street analysts, 19 analysts have made analyst ratings for Grifols SA, including 3 strong buy, 10 buy, 5 hold, 2 sell, and 3 strong sell
